Loading cancer entity…
Loading cancer entity…
Clinical trials
133 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (12)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04902443 | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | recruiting | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2026 | clinicaltrials |
| NCT02659930 | Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma | active not recruiting | Phase 1 | 62 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04941274 | Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma | recruiting | Phase 1 / Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04303117 | PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma | recruiting | Phase 1 / Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05859074 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | recruiting | Phase 1 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 79 | National Cancer Institute (NCI)NIH | 2 | Jan 21, 2026 | clinicaltrials |
| NCT07066982 | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas(BAH2573-103) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT05567601 | Doxil/Caelyx BE Study | completed | Phase 1 | 36 | Baxter Healthcare CorporationINDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT03157167 | An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS) | completed | Phase 1 | 15 | Navidea BiopharmaceuticalsINDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT02595866 | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | completed | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04893018 | NT-I7 for Kaposi Sarcoma in Patients With or Without HIV | terminated | Phase 1 | 8 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT00019188 | Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma | completed | Phase 1 / Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT01495598 | Pomalidomide for Kaposi Sarcoma in People With or Without HIV | completed | Phase 1 / Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Nov 1, 2022 | clinicaltrials |
| NCT01057121 | Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 / Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT00000987 | A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS | completed | Phase 1 | 36 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 4, 2021 | clinicaltrials |
| NCT00001113 | A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma | completed | Phase 1 | 48 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 4, 2021 | clinicaltrials |
| NCT00000660 | Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 | 24 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00000681 | A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma | completed | Phase 1 | 24 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00000725 | A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 | 56 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00000763 | A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 | 42 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00000694 | A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma | completed | Phase 1 | 18 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 2, 2021 | clinicaltrials |
| NCT00000695 | Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma | completed | Phase 1 | 36 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 2, 2021 | clinicaltrials |
| NCT00000954 | A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma | completed | Phase 1 | 72 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Oct 29, 2021 | clinicaltrials |
| NCT00000769 | A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma | completed | Phase 1 | 48 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Oct 28, 2021 | clinicaltrials |
| NCT00287495 | BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma | terminated | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT01752569 | A Study of Selumetinib in Patients With Kaposi's Sarcoma(SCART) | terminated | Phase 1 / Phase 2 | 19 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT00686842 | PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma | terminated | Phase 1 / Phase 2 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01016730 | Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Feb 20, 2018 | clinicaltrials |
| NCT02229981 | Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma(ABC-102) | withdrawn | Phase 1 / Phase 2 | 0 | RedHill Biopharma LimitedINDUSTRY | 1 | Dec 7, 2017 | clinicaltrials |
| NCT00581815 | Spectroscopy With Surface Coils and Decoupling | completed | Phase 1 | 582 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 28, 2015 | clinicaltrials |
| NCT00051597 | A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies | completed | Phase 1 / Phase 2 | 70 | Seagen Inc.INDUSTRY | 1 | Oct 12, 2011 | clinicaltrials |
| NCT00001535 | Twins Study of Gene Therapy for HIV Infection | completed | Phase 1 | 48 | National Human Genome Research Institute (NHGRI)NIH | 1 | Feb 8, 2008 | clinicaltrials |
| NCT00002136 | A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002137 | A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4 | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002138 | A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days. | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002153 | Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders | completed | Phase 1 | 25 | DEKK-TEC, Inc.INDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002262 | A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma | completed | Phase 1 | — | University of California, San FranciscoOTHER | 1 | Jun 24, 2005 | clinicaltrials |
| NCT00002342 | A Study of Tecogalan Sodium | completed | Phase 1 | — | Daiichi PharmaceuticalsINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
Data updated 12 days agoSource updated Sep 17, 2026source: clinicaltrials